Bristol-Myers Squibb Co vs Duolingo Inc — how do they compare? Bristol-Myers Squibb Co trades at $63.83 (market cap $129.94B), while Duolingo Inc trades at $129.36 (market cap $6.34B). The key difference: Bristol-Myers Squibb Co is far larger — about 20.5× Duolingo Inc's market cap, and Bristol-Myers Squibb Co pays a 3.96% dividend while Duolingo Inc pays none. Which is the better fit depends on your goals.
| BMY | DUOL | |
|---|---|---|
Market Cap | $129.94B | $6.34B |
Sector | Health | Technology |
52-Week High | $65.89 | $369.19 |
52-Week Low | $42.60 | $90.03 |
Enterprise Value | $163.92B | $5.11B |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Duolingo (DUOL) trades at $132.75, down 3.24% over 24 hours, with a bullish technical outlook from moving averages but neutral oscillators. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.66 versus $0.604 expected, driven by 23% daily active user growth. Revenue reached $1.04 billion in 2025, with net income surging to $414 million, though Q3 2026 revenue guidance fell short of expectations, causing recent stock pressure.
The investment outlook is mixed: robust user growth and profitability metrics like a 35.87% net margin support upside, but decelerating bookings growth and margin pressures from AI investments pose risks. Analysts show cautious optimism with a $121 consensus target, highlighting the stock's sensitivity to monetization trends amid competitive threats.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Duolingo Inc is a mobile learning platform to learn languages and the top-grossing app in the Education category on both Google Play and the Apple App Store. It has three predominant sources of revenue
Read more on DUOL →